Thomas 2007

1 Treatments

Studied treatment ixabepilone 40 mg/m(2) intravenously on day 1 of a 21-day cycle plus capecitabine 2,000 mg/m(2) orally on days 1 through 14 of a 21-day cycle

Control treatment capecitabine alone 2,500 mg/m(2) on days 1 through 14 of a 21-day cycle

Concomittant treatments -

2 Patients

Patients patients with metastatic breast cancer progressing after anthracycline and taxane treatment

Inclusion criteria -

Exclusion criteria -

3 Methods

Blinding open

Design Parallel groups

Centers -

Geographical area -

Sizes 752/0

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>overall survival</td>
<td>-/752</td>
<td>-/0</td>
<td>0,90</td>
<td>[0,77; 1,05]</td>
</tr>
<tr>
<td>PFS</td>
<td>-/752</td>
<td>-/0</td>
<td>0,75</td>
<td>[0,64; 0,88]</td>
</tr>
<tr>
<td>toxicity grade 3-4</td>
<td>-/752</td>
<td>-/0</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References


Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in